Literature DB >> 30111645

Finding useful biomarkers for Parkinson's disease.

Alice S Chen-Plotkin1, Roger Albin2,3, Roy Alcalay4, Debra Babcock5, Vikram Bajaj6, Dubois Bowman7, Alex Buko8, Jesse Cedarbaum9, Daniel Chelsky10, Mark R Cookson11, Ted M Dawson12, Richard Dewey13, Tatiana Foroud14, Mark Frasier15, Dwight German16, Katrina Gwinn5, Xuemei Huang17, Catherine Kopil15, Thomas Kremer18, Shirley Lasch19, Ken Marek19, Jarrod A Marto20,21,22, Kalpana Merchant23, Brit Mollenhauer24,25, Anna Naito15, Judith Potashkin26, Alyssa Reimer15, Liana S Rosenthal27, Rachel Saunders-Pullman28, Clemens R Scherzer29, Todd Sherer15, Andrew Singleton30, Margaret Sutherland5, Ines Thiele31, Marcel van der Brug32, Kendall Van Keuren-Jensen33, David Vaillancourt34, David Walt22, Andrew West35, Jing Zhang36.   

Abstract

The recent advent of an "ecosystem" of shared biofluid sample biorepositories and data sets will focus biomarker efforts in Parkinson's disease, boosting the therapeutic development pipeline and enabling translation with real-world impact.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30111645      PMCID： PMC6097233          DOI： 10.1126/scitranslmed.aam6003

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  31 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

Review 2.  Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease.

Authors:  Ronald B Postuma; Dag Aarsland; Paolo Barone; David J Burn; Christopher H Hawkes; Wolfgang Oertel; Tjalf Ziemssen
Journal:  Mov Disord       Date:  2012-04-15       Impact factor: 10.338

3.  Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Michal Figurski; Els Coart; Kaj Blennow; Holly Soares; Adam J Simon; Piotr Lewczuk; Robert A Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2011-02-11       Impact factor: 17.088

4.  CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.

Authors:  Guido Alves; Kolbjørn Brønnick; Dag Aarsland; Kaj Blennow; Henrik Zetterberg; Clive Ballard; Martin Wilhelm Kurz; Ulf Andreasson; Ole-Bjørn Tysnes; Jan Petter Larsen; Ezra Mulugeta
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-06-14       Impact factor: 10.154

Review 5.  Cerebrospinal fluid biomarkers in Parkinson disease.

Authors:  Lucilla Parnetti; Anna Castrioto; Davide Chiasserini; Emanuele Persichetti; Nicola Tambasco; Omar El-Agnaf; Paolo Calabresi
Journal:  Nat Rev Neurol       Date:  2013-02-19       Impact factor: 42.937

6.  Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation.

Authors:  Min Shi; James Movius; Romel Dator; Patrick Aro; Yanchun Zhao; Catherine Pan; Xiangmin Lin; Theo K Bammler; Tessandra Stewart; Cyrus P Zabetian; Elaine R Peskind; Shu-Ching Hu; Joseph F Quinn; Douglas R Galasko; Jing Zhang
Journal:  Mol Cell Proteomics       Date:  2015-01-02       Impact factor: 5.911

7.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

8.  Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease--Report of the JPND Working Group BioLoC-PD.

Authors:  Stefanie Lerche; Inga Liepelt-Scarfone; Guido Alves; Paolo Barone; Stefanie Behnke; Yoav Ben-Shlomo; Henk Berendse; David Burn; Richard Dodel; Donald Grosset; Sebastian Heinzel; Michele Hu; Meike Kasten; Rejko Krüger; Walter Maetzler; Marcello Moccia; Brit Mollenhauer; Wolfgang Oertel; Benjamin Roeben; Ulrike Sünkel; Uwe Walter; Karin Wirdefeldt; Daniela Berg
Journal:  Neuroepidemiology       Date:  2015-11-03       Impact factor: 3.282

9.  Why most published research findings are false.

Authors:  John P A Ioannidis
Journal:  PLoS Med       Date:  2005-08-30       Impact factor: 11.613

10.  The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases.

Authors:  Babette L R Reijs; Charlotte E Teunissen; Nikolai Goncharenko; Fay Betsou; Kaj Blennow; Inês Baldeiras; Frederic Brosseron; Enrica Cavedo; Tormod Fladby; Lutz Froelich; Tomasz Gabryelewicz; Hakan Gurvit; Elisabeth Kapaki; Peter Koson; Luka Kulic; Sylvain Lehmann; Piotr Lewczuk; Alberto Lleó; Walter Maetzler; Alexandre de Mendonça; Anne-Marie Miller; José L Molinuevo; Brit Mollenhauer; Lucilla Parnetti; Uros Rot; Anja Schneider; Anja Hviid Simonsen; Fabrizio Tagliavini; Magda Tsolaki; Marcel M Verbeek; Frans R J Verhey; Marzena Zboch; Bengt Winblad; Philip Scheltens; Henrik Zetterberg; Pieter Jelle Visser
Journal:  Front Neurol       Date:  2015-10-15       Impact factor: 4.003
View more
  34 in total

Review 1.  Biomarkers for Parkinson's Disease: How Good Are They?

Authors:  Tianbai Li; Weidong Le
Journal:  Neurosci Bull       Date:  2019-10-23       Impact factor: 5.203

2.  A novel multi-marker discovery approach identifies new serum biomarkers for Parkinson's disease in older people: an EXosomes in PArkiNson Disease (EXPAND) ancillary study.

Authors:  Riccardo Calvani; Anna Picca; Giovanni Landi; Federico Marini; Alessandra Biancolillo; Hélio José Coelho-Junior; Jacopo Gervasoni; Silvia Persichilli; Aniello Primiano; Annalaura Arcidiacono; Andrea Urbani; Maurizio Bossola; Anna Rita Bentivoglio; Matteo Cesari; Roberto Bernabei; Maria Rita Lo Monaco; Emanuele Marzetti
Journal:  Geroscience       Date:  2020-05-26       Impact factor: 7.713

3.  Plasma MIA, CRP, and Albumin Predict Cognitive Decline in Parkinson's Disease.

Authors:  Junchao Shen; Noor Amari; Rebecca Zack; R Tyler Skrinak; Travis L Unger; Marijan Posavi; Thomas F Tropea; Sharon X Xie; Vivianna M Van Deerlin; Richard B Dewey; Daniel Weintraub; John Q Trojanowski; Alice S Chen-Plotkin
Journal:  Ann Neurol       Date:  2022-06-07       Impact factor: 11.274

4.  A multiple-tissue-specific magnetic resonance imaging model for diagnosing Parkinson's disease: a brain radiomics study.

Authors:  Xiao-Jun Guan; Tao Guo; Cheng Zhou; Ting Gao; Jing-Jing Wu; Victor Han; Steven Cao; Hong-Jiang Wei; Yu-Yao Zhang; Min Xuan; Quan-Quan Gu; Pei-Yu Huang; Chun-Lei Liu; Jia-Li Pu; Bao-Rong Zhang; Feng Cui; Xiao-Jun Xu; Min-Ming Zhang
Journal:  Neural Regen Res       Date:  2022-12       Impact factor: 6.058

5.  Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease.

Authors:  Sara Hall; Christina D Orrù; Byron Caughey; Oskar Hansson; Geidy E Serrano; Douglas Galasko; Andrew G Hughson; Bradley R Groveman; Charles H Adler; Thomas G Beach
Journal:  Acta Neuropathol Commun       Date:  2022-06-22       Impact factor: 7.578

Review 6.  New Frontiers in Parkinson's Disease: From Genetics to the Clinic.

Authors:  Lamya S Shihabuddin; Patrik Brundin; J Timothy Greenamyre; Diane Stephenson; S Pablo Sardi
Journal:  J Neurosci       Date:  2018-10-31       Impact factor: 6.167

7.  Proteomics: techniques and applications in neuroscience.

Authors:  Mark R Cookson
Journal:  J Neurochem       Date:  2019-10-17       Impact factor: 5.372

8.  Cannabinoid Receptors and Ligands: Lessons from CNS Disorders and the Quest for Novel Treatment Venues.

Authors:  Clara M Vecchini Rodríguez; Yma Escalona Meléndez; Jacqueline Flores-Otero
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Simplified quantification of [18F]FE-PE2I PET in Parkinson's disease: Discriminative power, test-retest reliability and longitudinal validity during early peak and late pseudo-equilibrium.

Authors:  Joachim Brumberg; Vera Kerstens; Zsolt Cselényi; Per Svenningsson; Mathias Sundgren; Patrik Fazio; Andrea Varrone
Journal:  J Cereb Blood Flow Metab       Date:  2020-09-21       Impact factor: 6.200

Review 10.  Parkinson's Disease Drug Development Since 1999: A Story of Repurposing and Relative Success.

Authors:  Deirdre M Boucherie; Gonçalo S Duarte; Tiago Machado; Patrícia R Faustino; Cristina Sampaio; Olivier Rascol; Joaquim J Ferreira
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.